Cantor Fitzgerald is maintaining a bearish stance on equities, cautioning that the recent market rebound which has been driven largely by investor positioning—is likely behind us. The firm ...

On Monday, Cantor Fitzgerald analysts revised their stance on Onto Innovation Inc. (NYSE:ONTO), downgrading the stock from Overweight to Neutral and significantly reducing the price target to $135 ...

Fintel reports that on May 7, 2025, Cantor Fitzgerald downgraded their outlook for Marvell Technology (BMV:MRVL1) from Overweight to Neutral. There are 1,188 funds or institutions reporting ...

Fintel reports that on May 5, 2025, Cantor Fitzgerald downgraded their outlook for Onto Innovation (BMV:ONTO) from Overweight to Neutral. There are 501 funds or institutions reporting positions in ...

According to Cantor, this delay suggests “potential catalysts will be few and far between over the near- to medium-term.” Related articles Gilead Sciences to invest $11 billion in U.S. R&D and ...

On Tuesday, Cantor Fitzgerald analyst Sarah James reaffirmed an Overweight rating on CVS Health (NYSE:CVS) with a steady price target of $71.00. The rating aligns with the company’s strong ...

Now, Cantor Fitzgerald — backed by institutional muscle — is aiming to replicate Saylor’s success with even bigger ambitions. Along with stablecoin heavyweight Tether Holdings SA and ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The leading factor in the rating is the parent firm's five-year risk-adjusted success ratio of 71%.

On Tuesday, Cantor Fitzgerald analyst Sarah James reaffirmed an Overweight rating on CVS Health (NYSE:CVS) with a steady price target of $71.00. The rating aligns with the company’s strong market ...

Strategy stock opened at $385.86 on Monday. The firm has a market capitalization of $99.30 billion, a PE ratio of -68.50 and a beta of 3.79. Strategy has a one year low of $102.40 and a one year ...